• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Keywords » opioid-use-disorder

Items Tagged with 'opioid-use-disorder'

ARTICLES

Clinical Update

Xylazine: An Emerging Threat in the Opioid Overdose Epidemic

October 31, 2023
Roberto Sanchez, MD and Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Roberto Sanchez, MD. Addiction psychiatry fellow, Yale University School of Medicine, New Haven, CT.

Noah Capurso, MD, MHS. Assistant professor of psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Sanchez and Dr. Capurso have no financial relationships with companies related to this material.

Xylazine is the latest contaminant being found in the American illicit drug supply. A non-opioid itself, xylazine is usually combined with fentanyl, with which it has synergistic sedative effects. Patients using xylazine can have profound levels of sedation and develop severe peripheral wounds. In this article, we discuss xylazine essentials and cover harm reduction strategies to help keep your patients safe.


Read More

Unintended Pregnancies in Opioid Use Disorder

March 1, 2022
Peter J. Farago, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Peter J. Farago, MD. Dr. Farago has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Rates of unintended pregnancies are high among patients with opioid use disorder (OUD). In this study, researchers tested the efficacy of co-locating contraceptive services with treatment for OUD as well as the efficacy of providing financial incentives.
Read More

Buprenorphine Treatment

November 5, 2021
Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Noah Capurso, MDNoah Capurso, MD

Assistant Professor of Psychiatry at Yale University, CT. Editor-in-chief of The Carlat Addiction Treatment Report.

Dr. Capurso has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buprenorphine is a first line medication for the treatment of opioid use disorder yet remains vastly under-prescribed. Here, Dr. Capurso reviews the pharmacologic principles relevant to buprenorphine prescribing and lays out how to start patients on the medication both in the clinic and at home.
Read More

A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl

November 5, 2021
Oluwole Jegede, MD, PhD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Oluwole Jegede, MD. Dr. Jegede has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Avoiding buprenorphine induced withdrawal during induction can be particularly tricky for those using fentanyl. Researchers describe a novel induction dosing strategy that mitigates this risk.
Read More

Buprenorphine Induction Without Withdrawal

November 5, 2021
David Moltz, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
David Moltz, MD. Dr. Moltz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Making the switch from full opioid agonist to buprenorphine usually involves a period of withdrawal prior to starting the medication. Here, researchers describe a method of switching from full to partial opioid agonist by using small “microdoses” in order to avoid withdrawal.
Read More

Suboxone vs. Vivitrol for Opioid Use Disorder: How Do you Choose?

November 5, 2021
Gregory Lande, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Gregory Lande, MD. Dr. Lande has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Buprenorphine and long acting injectable naltrexone are both effective for the treatment of opioid use disorder; however, until now, we had little data to predict which patients would do better on which medications. Here, researchers identify patient characteristics predictive of success on buprenorphine versus naltrexone.
Read More

Naloxone Prescribing

July 3, 2021
Phillip Coffin, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Phillip Coffin, MDPhillip Coffin, MD
Director of Substance Use Research, San Francisco Department of Public Health, San Francisco, CA. Dr. Coffin has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Coffin provides our readers with everything there is to know about the nuts and bolts of naloxone prescribing for opioid use disorder. He tells us how patients can get their hands on naloxone, reviews the pros, cons, and costs of various naloxone formulations, and covers current naloxone laws.
Read More

A New High-Dose Naloxone: Life Saver or Punishment?

July 3, 2021
Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Noah Capurso, Editor-in-ChiefNoah Capurso, MD 

Dr. Capurso has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.


The FDA recently approved a nasal spray formulation of naloxone. Called Kloxxado, each spray delivers 8mg, twice as much as the most widely used formulation, Narcan. Whether or not this higher dose is necessary, is debatable.
Read More

Starting Buprenorphine: Is Timing Everything?

July 3, 2021
John O’Neal, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
John O’Neal, MD Dr. O’Neal has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
When is an optimal time to start buprenorphine in order to keep patients in treatment? In this retrospective study, researchers compared treatment retention as a function of whether or not buprenorphine was prescribed on the day of initial evaluation. Same day prescription trended non-significantly towards improved retention.
Read More
CLINICAL UPDATE

Perioperative Pain Management in Opioid Use Disorder

March 19, 2021
Rehan Aziz, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Previously, clinicians commonly stopped opioid agonists (methadone and buprenorphine) to simplify pain control during and after surgery. New guidance from the American Society of Addiction Medicine now suggests otherwise.
Read More
More Articles Tagged with 'opioid-use-disorder'
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.